After Hours Summary: KGJI +10.7%, HOLI +5.8%, NTAP +0.6%, NDLS -20.6%, CNAT -13.6%, XONE -9.1%, CSCO -1.3% following earnings/guidance
After Hours Gainers: Companies trading higher in after hours in reaction to earnings: KGJI +10.7%, HOLI +5.8%, AZPN +3%, IAG +2.6%, GEVO +2.1%, RMAX +1.4%, FRSH +1.2%, NTAP +0.6%
Companies trading higher in after hours in reaction to news: GSL +2.3% (announced pricing of depositary shares representing $35 mln of preferred stock at $25 per share), IQNT +1.9% (increased quarterly dividend 100% to $0.15 from $0.075 per share), PRSC +1.7% (to replace UNS Energy in the S&P SmallCap 600), PCP +1.0% (Board approved a $1 bln expansion to co's existing share repurchase program), PFE +0.8% (co confirmed that the Advisory Committee on Immunization Practices votes to recommend Prevnar 13 vaccine in adults aged 65 years and older), ORLY +0.1% (Board announced an additional $500 mln share repurchase authorization)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: NDLS -20.6%, CNAT -13.6%, VCYT -11.6%, TKMR -10.5%, YUME -9.1%, XONE -9.1%, VJET -7.2%, OCLR -5.8%, VIPS -4.4%, EXXI -4.2%, EMAN -4.1%, CIDM -3.9%, USU -2.2%, SLW -1.9%, INVE -1.9%, CSCO -1.3%, LPCN -0.2%
Companies trading lower in after hours in reaction to news: CNAT -13.6% (co said it is deferring the announcement of top-line results from the Phase 2 NAFLD/NASH clinical trial to Q1 2015; co also reported earnings), TKMR -10.5% (co remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola, expects matter to be resolved by Q4 2014; co also reported earnings), ENPH -5.7% (announced proposed public offering of common stock by selling stockholders), FSFR -3.9% (announced public offering of 22.8 mln shares of common stock), PDII -3.5% (co's subsidiary Interpace Diagnostics entered the molecular diagnostics market with thyroid and pancreatic cancer test portfolio acquisition of miRInform for $8 mln in upfront cash, future commercial milestone-based payments, and royalties), AMGN -2.2% (announced that the Phase 3 clinical trial FOCUS evaluating Kyprolis in patients with relapsed and advanced refractory multiple myeloma did not meet its primary endpoint), TKR -1.9% (announced proposed offering of $300 mln in senior notes due 2024), AMH -1.7% (announced public offering of 13 mln shares of Class A common shares)